FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2395282085> ?p ?o ?g. }

• W2395282085 endingPage "399" @default.
• W2395282085 startingPage "389" @default.
• W2395282085 abstract "Fabry disease, an X-linked glycosphingolipid storage disorder, is caused by the deficient activity of α-galactosidase A (α-Gal A). This results in the lysosomal accumulation in various cell types of its glycolipid substrates, including globotriaosylceramide (GL-3) and lysoglobotriaosylceramide (globotriaosyl lysosphingolipid, lyso-GL-3), leading to kidney, heart, and cerebrovascular disease. To complement and potentially augment the current standard of care, biweekly infusions of recombinant α-Gal A, the merits of substrate reduction therapy (SRT) by selectively inhibiting glucosylceramide synthase (GCS) were examined. Here, we report the development of a novel, orally available GCS inhibitor (Genz-682452) with pharmacological and safety profiles that have potential for treating Fabry disease. Treating Fabry mice with Genz-682452 resulted in reduced tissue levels of GL-3 and lyso-GL-3 and a delayed loss of the thermal nociceptive response. Greatest improvements were realized when the therapeutic intervention was administered to younger mice before they developed overt pathology. Importantly, as the pharmacologic profiles of α-Gal A and Genz-682452 are different, treating animals with both drugs conferred the greatest efficacy. For example, because Genz-682452, but not α-Gal A, can traverse the blood-brain barrier, levels of accumulated glycosphingolipids were reduced in the brain of Genz-682452-treated but not α-Gal A-treated mice. These results suggest that combining substrate reduction and enzyme replacement may confer both complementary and additive therapeutic benefits in Fabry disease." @default.
• W2395282085 created "2016-06-24" @default.
• W2395282085 creator A5019185950 @default.
• W2395282085 creator A5033862468 @default.
• W2395282085 creator A5034711909 @default.
• W2395282085 creator A5037882455 @default.
• W2395282085 creator A5040040696 @default.
• W2395282085 creator A5057984337 @default.
• W2395282085 creator A5058302196 @default.
• W2395282085 creator A5063202464 @default.
• W2395282085 creator A5069759535 @default.
• W2395282085 creator A5079813508 @default.
• W2395282085 creator A5090900773 @default.
• W2395282085 date "2015-01-01" @default.
• W2395282085 modified "2023-10-16" @default.
• W2395282085 title "Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease" @default.
• W2395282085 cites W1513228753 @default.
• W2395282085 cites W1942926606 @default.
• W2395282085 cites W1965222084 @default.
• W2395282085 cites W1975365119 @default.
• W2395282085 cites W1980743876 @default.
• W2395282085 cites W1983663909 @default.
• W2395282085 cites W1991004393 @default.
• W2395282085 cites W1994742615 @default.
• W2395282085 cites W1997235040 @default.
• W2395282085 cites W2011828022 @default.
• W2395282085 cites W2017903224 @default.
• W2395282085 cites W2034955397 @default.
• W2395282085 cites W2039534199 @default.
• W2395282085 cites W2041953538 @default.
• W2395282085 cites W2042318626 @default.
• W2395282085 cites W2045817726 @default.
• W2395282085 cites W2048797004 @default.
• W2395282085 cites W2049838934 @default.
• W2395282085 cites W2064528706 @default.
• W2395282085 cites W2064715246 @default.
• W2395282085 cites W2069784854 @default.
• W2395282085 cites W2071598008 @default.
• W2395282085 cites W2083805206 @default.
• W2395282085 cites W2090005375 @default.
• W2395282085 cites W2091164561 @default.
• W2395282085 cites W2094632651 @default.
• W2395282085 cites W2113915213 @default.
• W2395282085 cites W2125879510 @default.
• W2395282085 cites W2127086744 @default.
• W2395282085 cites W2136689144 @default.
• W2395282085 cites W2158749858 @default.
• W2395282085 cites W2160213856 @default.
• W2395282085 cites W2161318755 @default.
• W2395282085 cites W2163400476 @default.
• W2395282085 cites W2166859453 @default.
• W2395282085 cites W2313827278 @default.
• W2395282085 cites W2326936906 @default.
• W2395282085 cites W4250446838 @default.
• W2395282085 cites W2126914441 @default.
• W2395282085 doi "https://doi.org/10.2119/molmed.2015.00088" @default.
• W2395282085 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4559530" @default.
• W2395282085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25938659" @default.
• W2395282085 hasPublicationYear "2015" @default.
• W2395282085 type Work @default.
• W2395282085 sameAs 2395282085 @default.
• W2395282085 citedByCount "71" @default.
• W2395282085 countsByYear W23952820852015 @default.
• W2395282085 countsByYear W23952820852016 @default.
• W2395282085 countsByYear W23952820852017 @default.
• W2395282085 countsByYear W23952820852018 @default.
• W2395282085 countsByYear W23952820852019 @default.
• W2395282085 countsByYear W23952820852020 @default.
• W2395282085 countsByYear W23952820852021 @default.
• W2395282085 countsByYear W23952820852022 @default.
• W2395282085 countsByYear W23952820852023 @default.
• W2395282085 crossrefType "journal-article" @default.
• W2395282085 hasAuthorship W2395282085A5019185950 @default.
• W2395282085 hasAuthorship W2395282085A5033862468 @default.
• W2395282085 hasAuthorship W2395282085A5034711909 @default.
• W2395282085 hasAuthorship W2395282085A5037882455 @default.
• W2395282085 hasAuthorship W2395282085A5040040696 @default.
• W2395282085 hasAuthorship W2395282085A5057984337 @default.
• W2395282085 hasAuthorship W2395282085A5058302196 @default.
• W2395282085 hasAuthorship W2395282085A5063202464 @default.
• W2395282085 hasAuthorship W2395282085A5069759535 @default.
• W2395282085 hasAuthorship W2395282085A5079813508 @default.
• W2395282085 hasAuthorship W2395282085A5090900773 @default.
• W2395282085 hasBestOaLocation W23952820851 @default.
• W2395282085 hasConcept C126322002 @default.
• W2395282085 hasConcept C142724271 @default.
• W2395282085 hasConcept C181199279 @default.
• W2395282085 hasConcept C2776788019 @default.
• W2395282085 hasConcept C2776931407 @default.
• W2395282085 hasConcept C2777404818 @default.
• W2395282085 hasConcept C2777687718 @default.
• W2395282085 hasConcept C2779134260 @default.
• W2395282085 hasConcept C2779969927 @default.
• W2395282085 hasConcept C2909637497 @default.
• W2395282085 hasConcept C55493867 @default.
• W2395282085 hasConcept C71924100 @default.
• W2395282085 hasConcept C86803240 @default.
• W2395282085 hasConcept C98274493 @default.

• next